CL2012001841A1 - Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico. - Google Patents

Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico.

Info

Publication number
CL2012001841A1
CL2012001841A1 CL2012001841A CL2012001841A CL2012001841A1 CL 2012001841 A1 CL2012001841 A1 CL 2012001841A1 CL 2012001841 A CL2012001841 A CL 2012001841A CL 2012001841 A CL2012001841 A CL 2012001841A CL 2012001841 A1 CL2012001841 A1 CL 2012001841A1
Authority
CL
Chile
Prior art keywords
hyperuricemia
triazol
bromo
prevention
acetate
Prior art date
Application number
CL2012001841A
Other languages
English (en)
Inventor
Irina Zamansky
Galvin Gabriel
Jean-Luc Girardet
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of CL2012001841A1 publication Critical patent/CL2012001841A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN POLIMORFO CRISTALINO DE LA FORMA A DE 2- (5-BROMO-4-(4-CICLOPROPILNAFTA LEN-1-IL )-4H-1,2,4-TRIAZOL-3-ILTIO) ACETATO  DE SODIO. COMPOSICIÓN FARMACÉUTICA SÓLIDA QUE LO COMPRENDE. SU USO PARA EL TRATAMIENTO O PREVENCIÓN DE HIPERURICEMIA O UNA ENFERMEDAD CAUSADA POR NIVELES ELEVADOS DE ÁCIDO ÚRICO, Y UN METODO PARA PREPARAR DICHO POLIMORFO.<br />  
CL2012001841A 2010-01-08 2012-07-06 Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico. CL2012001841A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29360210P 2010-01-08 2010-01-08

Publications (1)

Publication Number Publication Date
CL2012001841A1 true CL2012001841A1 (es) 2013-08-23

Family

ID=44306123

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001841A CL2012001841A1 (es) 2010-01-08 2012-07-06 Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico.

Country Status (20)

Country Link
US (2) US8524754B2 (es)
EP (1) EP2521716B1 (es)
JP (1) JP5696346B2 (es)
KR (1) KR20120104627A (es)
CN (1) CN102741234B (es)
AU (1) AU2011203708B2 (es)
BR (1) BR112012016795A2 (es)
CA (1) CA2785200C (es)
CL (1) CL2012001841A1 (es)
CO (1) CO6561780A2 (es)
EA (1) EA020183B1 (es)
ES (1) ES2563207T3 (es)
HK (1) HK1172622A1 (es)
MX (1) MX2012007925A (es)
MY (1) MY161482A (es)
NZ (1) NZ600984A (es)
SG (1) SG182404A1 (es)
TW (1) TWI451867B (es)
WO (1) WO2011085009A2 (es)
ZA (1) ZA201204938B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3659601A1 (en) * 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
ES2670700T3 (es) * 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
SG190902A1 (en) * 2010-12-30 2013-07-31 Ardea Biosciences Inc Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof
CN106963761A (zh) 2011-11-03 2017-07-21 阿迪亚生命科学公司 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物
AR091651A1 (es) * 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
CN103524440B (zh) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
WO2015075561A2 (en) * 2013-11-22 2015-05-28 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad and its sodium salt
CN103588716A (zh) * 2013-11-22 2014-02-19 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的新晶型及其制备方法
CN103626710A (zh) * 2013-12-20 2014-03-12 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的共晶及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
CN105315218A (zh) * 2014-07-17 2016-02-10 天津药物研究院 一种制备lesinurad中间体1-萘基三唑硫酮的方法
CN105622427A (zh) * 2014-10-31 2016-06-01 天津药物研究院有限公司 一种制备lesinurad中间体4-环丙基-1-萘胺的方法
CN105820130B (zh) * 2015-01-08 2018-06-22 天津药物研究院有限公司 三氮唑正丙酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
CN105985296B (zh) * 2015-02-13 2018-10-16 天津药物研究院有限公司 一种可以工业化的lesinurad中间体1-萘基三唑硫酮的精制工艺
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
CN104817509B (zh) * 2015-04-13 2019-05-17 安徽省逸欣铭医药科技有限公司 Lesinurad类似物及其制备方法和医药用途
CN106187926B (zh) 2015-04-30 2018-11-27 天津药物研究院有限公司 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (zh) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 一种[4-(4-环丙基萘-1-基)-5-硝基- 4h-[1,2,4]三唑-3-基硫烷基]-乙酸乙酯的制备方法及其中间体(5-硝基-4h-[1,2,4]三唑-3-基硫基)-乙酸乙酯
CN105017168A (zh) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
CN105153056A (zh) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 一种[5-溴-4-(4-环丙基萘-1-基)-4h-[1,2,4]三唑-3-基硫烷基]-乙酸甲酯的新制备方法
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105566237B (zh) * 2016-03-01 2018-05-18 山东大学 一种治疗痛风的三唑巯乙酸类化合物的制备方法
CN107337649B (zh) * 2016-04-29 2020-10-16 四川科伦药物研究院有限公司 一种乙酸钠水合物无定型及其制备方法和用途
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
US10513500B2 (en) 2016-11-10 2019-12-24 Apotex Inc. Crystalline forms of Lesinurad
CN106632108A (zh) * 2016-12-14 2017-05-10 湖南欧亚生物有限公司 一种来司诺雷的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52632B (en) * 2004-08-25 2013-06-28 Ardea Biosciences Inc. S-TRIAZOLYL ALFA-MERCAPTOACETANILIDE AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EA201270666A1 (ru) 2007-11-27 2012-12-28 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EP2328879A4 (en) * 2008-09-04 2012-05-09 Ardea Biosciences Inc CORRESPONDING COMPOUNDS, COMPOSITIONS, AND METHODS OF USE FOR MODULATING URIC ACID RATES
SG190902A1 (en) 2010-12-30 2013-07-31 Ardea Biosciences Inc Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof

Also Published As

Publication number Publication date
CN102741234A (zh) 2012-10-17
MX2012007925A (es) 2012-08-03
TW201143767A (en) 2011-12-16
CN102741234B (zh) 2015-11-25
KR20120104627A (ko) 2012-09-21
JP5696346B2 (ja) 2015-04-08
BR112012016795A2 (pt) 2020-09-01
US20130345271A1 (en) 2013-12-26
WO2011085009A2 (en) 2011-07-14
HK1172622A1 (zh) 2013-04-26
WO2011085009A3 (en) 2011-11-10
EA020183B1 (ru) 2014-09-30
JP2013516473A (ja) 2013-05-13
CA2785200C (en) 2015-02-24
MY161482A (en) 2017-04-14
AU2011203708B2 (en) 2013-08-01
NZ600984A (en) 2013-10-25
CA2785200A1 (en) 2011-07-14
EA201270676A1 (ru) 2013-01-30
EP2521716A2 (en) 2012-11-14
SG182404A1 (en) 2012-08-30
ES2563207T3 (es) 2016-03-11
ZA201204938B (en) 2014-12-23
US20120129903A1 (en) 2012-05-24
US8524754B2 (en) 2013-09-03
EP2521716B1 (en) 2015-12-30
TWI451867B (zh) 2014-09-11
AU2011203708A1 (en) 2012-07-26
EP2521716A4 (en) 2013-07-10
CO6561780A2 (es) 2012-11-15

Similar Documents

Publication Publication Date Title
CL2012001841A1 (es) Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico.
BR112013016982A2 (pt) formas polimórficas de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acético e usos destes
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CL2014003475A1 (es) Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras.
BRPI0923217A2 (pt) processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica.
UY32490A (es) Inhibidores de beta-secretasa
BRPI1007645A2 (pt) &#34;composto de fórmula, composição, método para controlar fungos fitopatogênicos de colheitas e uso de compostos de fórmula&#34;
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
CL2010001368A1 (es) Compuestos derivados de 1,3-tiazina; composicion farmaceutica que lo comprende; utiles para inhibir a la beta-secretasa
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
EA201270216A1 (ru) Фармацевтический состав
BR112016015236A8 (pt) composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença.
SI2582683T1 (en) Treatment of gout and hyperuricaemia
PE20141148A1 (es) Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
CL2007003158A1 (es) Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
EP2560642A4 (en) TREATMENT OF GICHT
EP3060220A4 (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
WO2011006935A3 (en) Tetrazole derivatives
BRPI0912388A2 (pt) composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças
PH12017501397B1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
BRPI0909211B8 (pt) formulação oral em forma de comprimido de compostos de tetraciclina
PE20080175A1 (es) Sales de malato, y polimorfos de acido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico
BRPI0915130A2 (pt) derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c
BRPI0912890A2 (pt) composição farmacêutica para o tratamento de ejaculação precoce